ASSOCIATE PROF. DR. WAN ZAMANIAH BINTI WAN ISHAK @ WAN MOHAMMAD
Dean Office
Faculty of Medicine
zamachium.edu.myView CV | |
Publons | |
Biography | |
Associate Prof. Dr. Wan Zamaniah is a Consultant Clinical Oncologist at the University Malaya Medical Centre and University Malaya Specialist Centre, Kuala Lumpur, Malaysia. She graduated from University of Malaya, Kuala Lumpur Malaysia with Bachelor of Medicine & Bachelor of Surgery in 2001. Upon completion of her specialist training in clinical oncology in 2010 at the University of Malaya she joined University Malaya as a lecturer. She is a supervisor and coordinator for Master of Clinical Oncology programme as well as the University Malaya Medical programme at the Faculty of Medicine, UM. She is also actively doing research in clinical oncology field. She is also a council member of Malaysian Oncological Society, an Asia Pacific Regional council member for American Society of Clinical Oncology, a member of Academy of Medicine Malaysia, European Society for Medical Oncology and member of European Society of Radiation Oncology. Her areas of special interest include gastrointestinal cancers, head and neck cancers, gynaecological cancers and thyroid cancer. She is principle investigator for several international clinical trials mainly in gastrointestinal cancers and head and neck cancers. She published some of her works in the areas involved. She speaks in her areas of interest in both local and international scientific conferences. |
Publication
Finance
Project Title | Progress | Status |
---|---|---|
Geran Sanjungan Penyelidikan Mo021-2013 |
|
end |
This information is generated from Research Grant Management System |
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
Outcome for recurrent nasopharyngeal carcinoma in Malaysia: University Malaya Medical Centre, 2010-2019
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
<p>Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048</p>
Preliminary experience on the implementation of computed tomography (CT)-based image guided brachytherapy (IGBT) of cervical cancer using high-dose-rate (HDR) Cobalt-60 source in University of Malaya Medical Centre (UMMC)